ChemoMetec A/S (CHEMM.CO)
Copenhagen · DKK · Healthcare · Medical Devices
DKK 608.00 (-0.25%) as of
Key statistics
- Market cap
- 10.43B
- P/E (TTM)
- 52.41
- Forward P/E
- 36.93
- EPS (TTM)
- 11.60
- Dividend yield
- 0.00%
- 52-week range
- 235.20 – 804.00
- Beta
- 1.37
- Revenue (TTM)
- 511.06M
- Profit margin
- 39.49%
- Analyst target
- DKK 641.67
- Volume
- 24.68k
About ChemoMetec A/S
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter NC-203, a high-precision cell counter designed to deliver complex cell samples; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer. In addition, the company provides consumables comprising cassettes, reagents, lysis, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans and training. Further, it develops XcytoMatic 30 cell counter and Xcyto 5. ChemoMetec A/S was incorporated in 1997 and is headquartered in Allerød, Denmark.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Allerød, Denmark
- Employees
- 174
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.